Citadel Advisors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-41,717
| Closed | -$467K | – | 8818 |
|
|
2017
Q3 | $467K | Hold |
41,717
| – | – | ﹤0.01% | 5439 |
|
|
2017
Q2 | $459K | Hold |
41,717
| – | – | ﹤0.01% | 5246 |
|
|
2017
Q1 | $409K | Hold |
41,717
| – | – | ﹤0.01% | 5372 |
|
|
2016
Q4 | $451K | Sell |
41,717
-690
| -2% | -$6.9K | ﹤0.01% | 5064 |
|
|
2016
Q3 | $435K | Buy |
42,407
+1,400
| +3% | +$15.2K | ﹤0.01% | 5069 |
|
|
2016
Q2 | $536K | Buy |
41,007
+19,610
| +92% | +$257K | ﹤0.01% | 4393 |
|
|
2016
Q1 | $235K | Buy |
+21,397
| New | +$190K | ﹤0.01% | 5419 |
|
|
2015
Q3 | – | Sell |
-43,707
| Closed | -$429K | – | 9471 |
|
|
2015
Q2 | $429K | Sell |
43,707
-170,756
| -80% | -$1.56M | ﹤0.01% | 5215 |
|
|
2015
Q1 | $1.9M | Buy |
214,463
+93,768
| +78% | +$747K | ﹤0.01% | 3129 |
|
|
2014
Q4 | $1.06M | Buy |
120,695
+27,761
| +30% | +$225K | ﹤0.01% | 3699 |
|
|
2014
Q3 | $640K | Sell |
92,934
-12,120
| -12% | -$72.6K | ﹤0.01% | 4309 |
|
|
2014
Q2 | $552K | Sell |
105,054
-85,604
| -45% | -$417K | ﹤0.01% | 4267 |
|
|
2014
Q1 | $867K | Buy |
190,658
+72,329
| +61% | +$349K | ﹤0.01% | 3610 |
|
|
2013
Q4 | $596K | Buy |
+118,329
| New | +$569K | ﹤0.01% | 3805 |
|
|
2013
Q3 | – | Sell |
-11,594
| Closed | -$58K | – | 6988 |
|
|
2013
Q2 | $58K | Buy |
+11,594
| New | +$55.2K | ﹤0.01% | 5582 |
|
Citadel Advisors's SCLN Position: Q4 2017 in Review
Citadel Advisors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 41,717 shares — an estimated $467K sold.
Citadel Advisors first reported a position in SCLN in Q2 2013 and held it in 15 quarters. The position peaked at $1.9M in Q1 2015. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Citadel Advisors reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Citadel Advisors sold 41,717 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $467K.
- Citadel Advisors first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
- Citadel Advisors's Sciclone Pharmaceuticals Inc position peaked at $1.9M in Q1 2015.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.